Sign in
PYXS Stock Price, Chart, Stats & News
Pyxis Oncology, Inc.
Save
Pyxis Oncology, Inc. (PYXS) does not currently pay a dividend.
160.29M
Market cap
–
Current P/E
–
Forward P/E
PYXS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 103.12% |
Operating margin | -609.18% |
Pretax margin | -564.55% |
Net margin | -574.55% |
Effective tax rate | -1.77% |
ROA | -87.00% |
ROE | -101.77% |
D/E | 0.35x |
Interest coverage ratio | – |
PYXS valuation
P/E | – |
P/S | 5.94x |
P/B | 1.52x |
P/CF | -1.28x |
P/FCF | -1.30x |
P/OCF | -1.28x |
PEG | -0.06x |
EV multiple | -0.99x |
About
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors.
Similar securities
Based on sector and market capitalization
Report issue